Amsterdam, the Netherlands - May 14-15, 2025
SeekIn Inc., a leader in blood-based cancer early detection and monitoring technology, unveiled cost-effective Two-Step multi-cancer screening strategy and breakthrough lung cancer early detection test at NKI Early Cancer Detection Conference 2025, ushering in a new era of cancer screening.
1. Two-Step Multi-Cancer Screening Strategy
The new technologies in cancer screening currently face challenges such as high false-positive rates and costly procedures. SeekIn has developed a two-step screening strategy that significantly reduces false positives and alleviates the financial burden of population-wide screening, offering more affordable Multi-Cancer Early Detection (MCED).
In two-step approach, the initial screening is conducted using OncoSeek® (blood-based low-cost multi-cancer early detection test), followed by confirmation with SeekInCare® (blood-based pan-cancer early detection test) for positive cases. In a study involving 1197 individuals (617 cancer patients and 580 non-cancer individuals), the approach dramatically decreased the false-positive rate from 9.0% to 0.7% (a 12.9-fold reduction). In a simulation of screening 5 million individuals, compared to a NGS-based MCED test, the approach reduced total screening costs by 6.6 times and costs per cancer patient by 5.2 times.
2. Lung cancer early detection with LungCanSeek®
SeekIn also presented its LungCanSeek® test, a blood-based, non-invasive, and cost-effective solution for lung cancer early detection. In a study of 1,814 participants (1,095 with lung cancer and 719 without cancer) from three cohorts, LungCanSeek® showed 83.5% sensitivity and 90.3% specificity by combining artificial intelligence (AI) algorithms with four protein tumor markers (PTMs). Moreover, LungCanSeek® can also predict the possible histological subtypes. With a 77.4% subtype classification accuracy, it could offer valuable guidance for subsequent diagnosis and treatment.
For lung cancer screening, SeekIn also recommends a two-step strategy: initial screening with LungCanSeek®, followed by low-dose computed tomography (LDCT) imaging for positive cases. This integrated approach leverages the strengths of both tests, reducing false positives by over 10-fold and costs by 2.5-fold compared to sole LDCT screening in high-risk populations.
About NKI Early Cancer Detection Conference 2025
The inaugural NKI Early Cancer Detection Conference 2025 was organized by the Netherlands Cancer Institute (NKI). The conference bringing together experts and professionals dedicated to advancing early cancer detection. This event offers a unique opportunity to connect and collaborate within the early detection community.
The Netherlands Cancer Institute is among the world’s best comprehensive cancer centers, committed to providing rapid and accurate diagnoses, utilizing the latest methods, techniques and state-of-the-art equipment.